BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36231102)

  • 1. ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.
    Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
    Ahmed N; Riley C; Oliva K; Rice G; Quinn M
    Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK; Gertz RE; Ivins CM; Kacinski BM
    Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential roles of uPAR in peritoneal ovarian carcinomatosis.
    Al-Hassan NN; Behzadian A; Caldwell R; Ivanova VS; Syed V; Motamed K; Said NA
    Neoplasia; 2012 Apr; 14(4):259-70. PubMed ID: 22577342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
    Jo M; Takimoto S; Montel V; Gonias SL
    Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
    Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
    Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
    Lizalek J; McKenna T; Huegel K; Marsh S; Carolan A; Kobliska A; Heying E; Gardner N; Miller G; Kotecki A; Henningsen M; Lundt A; Farley J; Ellerbroek SM
    Anticancer Res; 2015 Oct; 35(10):5263-70. PubMed ID: 26408685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
    Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
    Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.
    Ding Y; Zhang H; Zhong M; Zhou Z; Zhuang Z; Yin H; Wang X; Zhu Z
    Eur J Med Res; 2013 Aug; 18(1):28. PubMed ID: 23985164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.
    Merino P; Diaz A; Jeanneret V; Wu F; Torre E; Cheng L; Yepes M
    J Biol Chem; 2017 Feb; 292(7):2741-2753. PubMed ID: 27986809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
    Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
    Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
    FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
    Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
    Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.